August 16, 2018 9:37am

Indication intelligence collects and analyzes sector information to sort-out weaknesses, vulnerabilities and strengths


I know you have seen, read and appreciate RMi’s interpretation and sometimes clarification of news, perception and actionable intelligence including a pricing metric.


I make a commitment to provide need-to-know “facts in evidence” with first, fast, and furious editions of what’s happening in the cell and gene therapy, immune-oncology and regenerative medicine sector even as or before news unfolds!

Now I’m asking you to commit 

Insight is developed from a real-time perspective to determine an equity’s attractiveness as stock pricing changes by the hour … if not the minute!

Every business day, RegMed Investors offers you:

  • Critical Knowledge Ahead of the Market Open:  the pre-open thesis …  a prognosis of what could or should happen or might not;
  • Interpretation, Insight and Translation: An exclusive look at how sector companies are evolving their platforms and trial statuses in an ever-changing market. Our deep-dive reporting of news and issues reflects ever-changing pattern analysis tempered by advance/decline lines as well as current tracking of evolving indexes and indices;
  • Capital Market Access: A run-down on not just which companies are filing for offerings, but also a complete analysis of their size and warrant coverage, At-the-Market (ATM) facilities, debt vehicles, and the price extended to investors;
  • Companies to Watch: The “stats”, latest updates, and "What's-the-Price" analysis of “our” universe’s latest news includes the break-down of quarterly (Q) and fiscal year (FY) earnings and never forget the “dogs” of our universe;
  • Actionable Intelligence:  Full breakdowns that highlight the impact of trials, developments, platforms and partnerships.


SUBSCRIBE TO RegMed Investors at